Bone Biologics's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bone Biologics (BBLG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bone Biologics vs Its Competitors
- Scale: Bone Biologics ranks #208 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Bone Biologics's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bone Biologics Corporation | - | - | - | Yes |
| Competitors combined (26) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BBLG Stock Performance relative to its Competitors
BBLG Stock Performance relative to High-Confidence Competitors
BBLG Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Tenon Medical Inc | 282.9% | Outperformed |
| 2 | Monogram technologies inc | 282.9% | Outperformed |
| 3 | Bioventus Inc | 282.9% | Outperformed |
| 4 | Globus Medical Inc | 282.9% | Outperformed |
| 5 | Si bone inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bone Biologics's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bone Biologics's Comment on Competition and Industry Peers
Publicly Traded Peers of Bone Biologics Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Bone Biologics Corporation | 0.87 | - |
| Medtronic Plc | 115,016.45 | 37,542.00 |
| Stryker Corp | 106,269.66 | 25,837.00 |
| Edwards Lifesciences Corporation | 50,153.01 | 6,512.50 |
| Zimmer Biomet Holdings Inc | 17,464.79 | 8,508.80 |
| Smith and Nephew Plc | 11,820.42 | 6,164.00 |
| SUBTOTAL | 326,508.02 | 98,206.59 |
Sign in to see all competitors of Bone Biologics Corporation.
Sources: Bone Biologics Corporation's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bone Biologics Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bone Biologics's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medtronic | Named by the company | 85% |
| Stryker | Named by the company | 85% |
| Zimmer-Biomet | Named by the company | 85% |
| DePuy-Synthes | Named by the company | 85% |
| Globus Medical | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bone Biologics's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Bone Biologics's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bone Biologics Corporation | 1 | - | - |
| Medtronic Plc | 115,016 | 395,179 | 55,463 |
| Stryker Corp | 106,270 | 461,375 | 66,589 |
| Edwards Lifesciences Corporation | 50,153 | 407,031 | 62,725 |
| Zimmer Biomet Holdings Inc | 17,465 | 500,518 | 47,476 |
| Smith and Nephew Plc | 11,820 | 362,844 | 36,791 |
| PEERS TOTAL | 326,507 | 399,021 | 38,639 |
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.26 % |
| Globus Medical Inc | United States 79.61 % |
| Alphatec Holdings Inc | US 94.22 % |
| Conmed Corporation | United States 51.06 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Edwards Lifesciences Corporation | United States 57.64 % |
| Globus Medical Inc | Reportable 100.00 % |
| Teleflex Incorporated | Americas 60.77 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Bone Biologics's industry classification, broader than the peer set above. Market cap in millions of $.Bone Biologics ranks #208 of 222 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 587, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 145,832 | 13.38 % |
| 2 | Medtronic Plc | 113,372 | 10.40 % |
| 3 | Stryker Corp | 105,405 | 9.67 % |
| 4 | 3m Company | 88,542 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 208 | Bone Biologics Corporation | 1 | 0.00 % |
Market cap and industry share for the rest of Bone Biologics's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Bone Biologics's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 203 | Fuse Medical Inc | 2 | - |
| 204 | Vsee Health Inc | 2 | - |
| 205 | Nu med Plus Inc | 1 | -53.21 % |
| 206 | Regentis Biomaterials Ltd | 1 | - |
| 207 | Logicmark Inc | 1,234 | 12.3% |
| 208 | Bone Biologics Corporation | 1 | -77.23 % |
| 209 | Mountain Crest Acquisition Corp V | 1,234 | 12.3% |
| 210 | Glucotrack Inc | 1,234 | 12.3% |
| 211 | Encision Inc | 1,234 | 12.3% |
| 212 | Therapeutic Solutions International Inc | 1,234 | 12.3% |
| 213 | Vicarious Surgical Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bone Biologics's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bone Biologics's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (288 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 34.6x | - |
| EV / EBITDA | - | 19.7x | - |
| P/B | 0.5x | 4.7x | -4.3x |
| Return on Equity | -57.85 % | industry aggregate | -69.91 % |
| Return on Invested Capital | -30.63 % | -2.32 % (avg) | -28.31 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bone Biologics's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | 26.86 % | 12.74 % | -2.78 % | 11.78 % | -32.76 % | -125.15 % | -60.88 % | -30.95 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bone Biologics's BCG Growth-Share Matrix
Relative market share (vs Bone Biologics's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) — a common framework, not a precision instrument.
Bone Biologics falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 9.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bone Biologics's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 587 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Bone Biologics's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Bone Biologics's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Bone Biologics's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Bone Biologics falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bone Biologics's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 69.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Bone Biologics's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bone Biologics Corporation | 12.67 | 13.70 | - |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
| Zimmer Biomet Holdings Inc | 0.25 | 1.93 | 0.60 |
| Smith and Nephew Plc | 0.35 | 2.57 | - |
Sign in to see all peers for Bone Biologics Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bone Biologics's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bone Biologics Corporation | Q2 2026 | - | - |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +4.8 % | +30.1 % |
| Smith and Nephew Plc | Q4 2025 | +6.1 % | +51.7 % |
| PEERS TOTAL | +8.4 % | +58.0 % |
Sign in to see all peers for Bone Biologics Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bone Biologics's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bone Biologics Corporation | Q2 2026 | - | - |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +7.3 % | +45.3 % |
| Smith and Nephew Plc | Q4 2025 | +6.2 % | - |
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bone Biologics Corporation | - | - | - |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
| Zimmer Biomet Holdings Inc | 3.51% | 3.97% | 6.36% |
| Smith and Nephew Plc | 5.98% | 5.98% | 11.82% |
Sign in to see all peers for Bone Biologics Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bone Biologics's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bone Biologics Corporation | - | - |
| Medtronic Plc | 263.24 | 3.06 |
| Stryker Corp | 28.53 | 4.11 |
| Edwards Lifesciences Corporation | 49.99 | 7.70 |
| Zimmer Biomet Holdings Inc | 22.04 | 2.05 |
| Smith and Nephew Plc | 37.82 | 1.92 |
| PEERS AVERAGE | 34.34 | 3.32 |
Sign in to see all peers for Bone Biologics Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.